Traffic Noise Studies Clause Samples

Traffic Noise Studies. 14.1 Perform a traffic noise analysis in accordance with the current version of the State’s (FHWA approved) “Guidelines for Analysis and Abatement of Roadway Traffic Noise” The current version of the guidance is located on the State’s Traffic Noise Toolkit website located at ▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇/inside-txdot/division/environmental/compliance-toolkits.html. Noise analyses shall be performed for all alternatives. 14.2 Comply with all noise policy, guidelines and standards found on the State’s Traffic Noise Toolkit website located at ▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇/inside-txdot/division/environmental/compliance- toolkits.html. . Upon request, the State shall provide the Engineer’s Technical Expert with existing and predicted (future) traffic data and, when available, aerial photography. 14.3 By project location site visit, identify adjacent, land use development and photo document representative receivers that might be impacted by highway traffic noise and may benefit from feasible and reasonable noise abatement. 14.4 Determine existing and predicted noise levels for representative receivers, as follows: 14.4.1 For transportation activities on new location, take field measurements of existing noise levels. Field measurements shall be accomplished with sound meters that meet or exceed American National Standards Institute (ANSI) S1.4-1983, Type 2. 14.4.2 For transportation activities not on new location, perform computer modeling of existing noise levels and predicted (future) noise levels. 14.4.3 Computer modeling shall be accomplished with the latest FHWA approved Traffic Noise Model (TNM) software program which must be purchased at the expense of the Engineer’s Technical Expert from the software distributor. 14.5 Identify impacted receivers in accordance with the absolute and relative impact criteria. 14.6 Consider and evaluate all required noise abatement measures for impacted receivers in accordance with the feasible and reasonable criteria. 14.7 Propose noise abatement measures that are both feasible and reasonable. 14.8 Determine predicted (future) noise impact contours for transportation activities where there is adjacent undeveloped property where residential or commercial development is likely to occur in the near future.
View SourceView Similar (34)
Traffic Noise Studies. The Engineer shall: a. Perform a traffic noise analysis in accordance with the current version of the State’s (FHWA approved) “Guidelines for Analysis and Abatement of Roadway Traffic Noise.” Noise analyses shall be performed for all alternatives. b. The State will provide a copy of the current version of the guidelines. Upon request, the State shall provide the Engineer’s Technical Expert with existing and predicted (future) traffic data and, when available, aerial photography. c. By project location site visit, identify adjacent, land use development and photo document representative receivers that might be impacted by highway traffic noise and may benefit from feasible and reasonable noise abatement. d. Determine existing and predicted noise levels for representative receivers, as follows: 1) For transportation activities on new location, take field measurements of existing noise levels. Field measurements shall be accomplished with sound meters that meet or exceed American National Standards Institute (ANSI) S1.4-1983, Type 2. 2) For transportation activities not on new location, perform computer modeling of existing noise levels and predicted (future) noise levels. 3) Computer modeling shall be accomplished with the latest FHWA approved Traffic Noise Model (TNM) software program which must be purchased at the Technical Expert’s expense from the software distributor. e. Identify impacted receivers in accordance with the absolute and relative impact criteria. f. Consider and evaluate all required noise abatement measures for impacted receivers in accordance with the feasible and reasonable criteria. g. Propose noise abatement measures that are both feasible and reasonable. h. Determine predicted (future) noise impact contours for transportation activities where there is adjacent undeveloped property where residential or commercial development is likely to occur in the near future.
View SourceView Similar (6)
Traffic Noise Studies. The Engineer shall:
View SourceView Similar (2)
Traffic Noise Studies. The Engineer shall: a. Perform a traffic noise analysis in accordance with the current version of the State’s (FHWA approved) “Guidelines for Analysis and Abatement of Roadway Traffic Noise” The current version of the guidance is located on the State’s Traffic Noise Toolkit website located at ▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇/inside- txdot/division/environmental/compliance-toolkits.html. Noise analyses shall be performed for all alternatives.
View Source

Related to Traffic Noise Studies

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in ▇▇▇▇ rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;